Amgen beefs up its late-stage pipeline with a $400M cash deal to go up against heavyweight rivals in a PhIII atopic dermatitis showdown

Three months after Kyowa Kirin claimed a hit for their mid-stage program testing the anti-OX40 antibody KHK4083 for moderate to severe atopic dermatitis, Amgen is going all-in on the drug, paying $400 million in cash to line up ex-Japan rights in what’s shaping up as another big, late-stage rivalry in…

...

Click to view original post